Literature DB >> 26730161

Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer.

Osamu Kinoshita1, Daisuke Ichikawa1, Yusuke Ichijo1, Shuhei Komatsu1, Kazuma Okamoto1, Mitsuo Kishimoto1, Akio Yanagisawa1, Eigo Otsuji1.   

Abstract

AIM: To investigate the effect of preoperative chemotherapy (pre-CTx) for metastatic lymph nodes (MLNs) of gastric cancer (GC).
METHODS: A retrospective cohort of patients with advanced GC, who underwent pre-CTx followed by gastrectomy, was reviewed. The histological tumor regression grade (TRG), which considered the percentage of residual cancer in the visible tumor bed, was applied to primary tumors and individual MLNs: G1a (complete response), G1b (< 10%), G2 (10%-50%) and G3 (> 50%). The clinical response to pre-CTx was retrospectively evaluated using only MLNs information, and we compared the histological and clinical evaluations of MLNs.
RESULTS: Twenty-eight patients were enrolled. A total of 438 MLNs were retrieved, and 22 (5%), 48 (11%), 63 (14%) and 305 (70%) LNs were assigned as G1a, G1b, G2 and G3, respectively. Stratification of the residual MLNs based on the TRGs was as follows: 28 G1b MLNs (9%), 48 G2 MLNs (15%), and 253 G3 MLNs (76%) in the D1 region; 20 (23%), 15 (17%), and 52 (60%) in the D2 region, respectively. However, no significant correlation was found between TRGs in MLNs and clinical response in the subgroup for which evaluation of clinical response was available.
CONCLUSION: Pre-CTx does not provide any outstanding histological benefit for MLNs, and an appropriate D2 lymphadenectomy should routinely be performed to offer the chance of curative resection.

Entities:  

Keywords:  Gastric cancer; Histological regression grade; Lymphadenectomy; Metastatic lymph node; Preoperative chemotherapy

Mesh:

Year:  2015        PMID: 26730161      PMCID: PMC4690179          DOI: 10.3748/wjg.v21.i48.13500

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial.

Authors:  Shahriyar Hashemzadeh; Ali Pourzand; Mohammad Hossein Somi; Sina Zarrintan; Reza Javad-Rashid; Ali Esfahani
Journal:  Int J Surg       Date:  2014-08-23       Impact factor: 6.071

2.  Japanese gastric cancer treatment guidelines 2010 (ver. 3).

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

3.  Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy.

Authors:  Tsutomu Hayashi; Toru Aoyama; Kazuaki Tanabe; Kazuhiro Nishikawa; Yuichi Ito; Takashi Ogata; Haruhiko Cho; Satoshi Morita; Yumi Miyashita; Akira Tsuburaya; Junichi Sakamoto; Takaki Yoshikawa
Journal:  Ann Surg Oncol       Date:  2014-04-09       Impact factor: 5.344

Review 4.  Critical determinants of metastasis.

Authors:  Isaiah J Fidler
Journal:  Semin Cancer Biol       Date:  2002-04       Impact factor: 15.707

Review 5.  Gastric cancer and the epoch of immunotherapy approaches.

Authors:  Elena Niccolai; Antonio Taddei; Domenico Prisco; Amedeo Amedei
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

6.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

7.  Evaluation of lymph nodes with RECIST 1.1.

Authors:  L H Schwartz; J Bogaerts; R Ford; L Shankar; P Therasse; S Gwyther; E A Eisenhauer
Journal:  Eur J Cancer       Date:  2008-12-16       Impact factor: 9.162

8.  Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.

Authors:  E Mochiki; T Ohno; Y Kamiyama; R Aihara; N Haga; H Ojima; J Nakamura; H Ohsawa; T Nakabayashi; K Takeuchi; T Asao; H Kuwano
Journal:  Br J Cancer       Date:  2006-11-28       Impact factor: 7.640

9.  Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002.

Authors:  Guillaume Piessen; Mathieu Messager; Karine Le Malicot; William B Robb; Frédéric Di Fiore; Marie Guilbert; Marie Moreau; Véronique Christophe; Antoine Adenis; Christophe Mariette
Journal:  BMC Cancer       Date:  2013-06-10       Impact factor: 4.430

10.  D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy.

Authors:  Shailesh V Shrikhande; Savio G Barreto; Sanjay D Talole; Kumar Vinchurkar; Somashekar Annaiah; Kunal Suradkar; Shaesta Mehta; Mahesh Goel
Journal:  World J Surg Oncol       Date:  2013-02-02       Impact factor: 2.754

View more
  8 in total

Review 1.  Prognostic impact of nodal status and therapeutic implications.

Authors:  Katja Ott; Susanne Blank; Laura Ruspi; Margit Bauer; Leila Sisic; Thomas Schmidt
Journal:  Transl Gastroenterol Hepatol       Date:  2017-03-15

2.  Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial.

Authors:  Cas de Jongh; Lianne Triemstra; Arjen van der Veen; Lodewijk A A Brosens; Misha D P Luyer; Jan H M B Stoot; Jelle P Ruurda; Richard van Hillegersberg
Journal:  Gastric Cancer       Date:  2022-09-14       Impact factor: 7.701

3.  Short-term outcomes of laparoscopic versus open total gastrectomy after neoadjuvant chemotherapy: a cohort study using the propensity score matching method.

Authors:  Yinkui Wang; Xiaokang Lei; Zining Liu; Fei Shan; Xiangji Ying; Ziyu Li; Jiafu Ji
Journal:  J Gastrointest Oncol       Date:  2021-04

4.  Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.

Authors:  Patricia Martin-Romano; Jose J Sola; Juan A Diaz-Gonzalez; Ana Chopitea; Yohana Iragorri; Fernando Martínez-Regueira; Mariano Ponz-Sarvise; Leire Arbea; Jose C Subtil; David Cano; Lucia Ceniceros; Jairo Legaspi; Jose Luis Hernandez; Javier Rodríguez
Journal:  Br J Cancer       Date:  2016-08-18       Impact factor: 7.640

5.  The prognostic value of negative lymph node count for patients with gastric cancer who received preoperative radiotherapy.

Authors:  Xinxing Li; Weigang Zhang; Xianwen Zhang; Haolu Wang; Kai Xu; Houshan Yao; Jun Yao; Xiaowen Liang; Zhiqian Hu
Journal:  Oncotarget       Date:  2017-07-18

6.  Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study.

Authors:  Maria Antonietta Mazzei; Giulio Bagnacci; Francesco Gentili; Andrea Nigri; Veronica Pelini; Carla Vindigni; Francesco Giuseppe Mazzei; Gian Luca Baiocchi; Frida Pittiani; Paolo Morgagni; Enrico Petrella; Gianni Mura; Beatrice Verdelli; Maria Bencivenga; Simone Giacopuzzi; Daniele Marrelli; Franco Roviello; Luca Volterrani
Journal:  Gastroenterol Res Pract       Date:  2018-03-15       Impact factor: 2.260

7.  Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.

Authors:  Daniel Reim; Alexander Novotny; Helmut Friess; Julia Slotta-Huspenina; Wilko Weichert; Katja Ott; Bastian Dislich; Sylvie Lorenzen; Karen Becker; Rupert Langer
Journal:  J Pathol Clin Res       Date:  2020-05-13

8.  Short-Term Clinical Efficacy of Neoadjuvant Chemotherapy Combined With Laparoscopic Gastrectomy for Locally Advanced Siewert Type II and III Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Propensity Score-Matched Study.

Authors:  Qing Feng; Du Long; Ming-Shan Du; Xiao-Song Wang; Zhen-Shun Li; Yong-Liang Zhao; Feng Qian; Yan Wen; Pei-Wu Yu; Yan Shi
Journal:  Front Oncol       Date:  2021-09-29       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.